A potential therapeutic target to enhance vasodilation and thereby reduce portal hypertension is soluble guanylate cyclase (sGC), an enzyme acting as a receptor for the vasodilator nitric oxide (NO). The gene discussed is SGCB; the disease is liver disorder.